Orna Therapeutics and Simnova Strengthen Alliance with New BCMA RNA Therapies Initiative
In a significant advancement in the field of RNA therapeutics, Orna Therapeutics, Inc. and Shanghai Simnova Biotech Co., Ltd. have announced the expansion of their strategic collaboration, now focusing on BCMA (B-cell maturation antigen) targeted therapies. This exciting development comes as both companies strive to enhance treatment modalities for patients around the globe.
This partnership aims to leverage Orna’s innovative circular RNA (oRNA®) technology alongside Simnova's advanced expertise in cell therapy. Under the terms of the agreement, Simnova will be responsible for the research, development, and commercialization of in vivo panCAR cell therapies that specifically target BCMA within the Greater China market. Meanwhile, Orna retains all development and commercialization rights for the rest of the world, ensuring a global impact with their revolutionary therapies.
As part of their collaboration, both parties will benefit from an initial payment pertaining to their specific territories, alongside eligibility for various milestone payments tied to clinical development, regulatory approvals, and commercialization achievements, culminating in royalties from any resultant approved products.
Previously, in January 2023, the duo had entered a collaboration agreement which granted Simnova exclusive rights to exploit Orna’s in vivo cell therapy products specifically in the Greater China area, including the promising ORN-101 project that targets CD19.
Dr. Ansbert Gadicke, Chairman of Orna and Managing Partner at MPM BioImpact, expressed enthusiasm over this enhanced collaboration, stating, “We are thrilled to deepen our partnership with Simnova to introduce an in vivo BCMA panCAR therapy specifically for patients suffering from multiple myeloma.” He emphasized that Orna’s unique panCAR approach aims to transcend the limitations associated with conventional ex vivo cell therapies. The pre-clinical and non-human primate data produced by Orna continues to reinforce their commitment to advancing these groundbreaking therapies toward clinical practice.
Dr. Zhuoxiao Cao, the CEO of Simnova, echoed these sentiments, affirming that their mutual dedication to developing immunotherapies and oncology treatments presents new avenues for addressing urgent medical needs through the strategic development of BCMA-targeted therapeutics.
Orna Therapeutics is at the forefront of designing and delivering a new class of fully engineered circular RNA therapeutics, intended to harness the transformative potential of RNA medicine in combating a variety of diseases. The company’s circular RNA transcripts offer several advantages over traditional mRNA technologies, particularly in terms of simplified production processes and enhanced protein expression through advanced lipid nanoparticle (LNP) delivery systems. Their robust capabilities position Orna as a key player in the evolution of RNA therapeutics, with the potential to significantly enhance patient treatment paradigms.
Shanghai Simnova Biotech, dedicated to pioneering innovative cell therapy solutions for oncology and autoimmune diseases, boasts a rich research and development pipeline, highlighted by their proprietary universal off-the-shelf CAR-NK and BiTE CAR-T programs. With several products currently at various stages of clinical development, Simnova is poised to make substantial contributions to the realm of biotherapeutics.
For more information, visit Orna Therapeutics at www.ornatx.com and Simnova Biotech at www.simnovabio.com.
Expanded Collaboration Details
This partnership aims to leverage Orna’s innovative circular RNA (oRNA®) technology alongside Simnova's advanced expertise in cell therapy. Under the terms of the agreement, Simnova will be responsible for the research, development, and commercialization of in vivo panCAR cell therapies that specifically target BCMA within the Greater China market. Meanwhile, Orna retains all development and commercialization rights for the rest of the world, ensuring a global impact with their revolutionary therapies.
As part of their collaboration, both parties will benefit from an initial payment pertaining to their specific territories, alongside eligibility for various milestone payments tied to clinical development, regulatory approvals, and commercialization achievements, culminating in royalties from any resultant approved products.
Previously, in January 2023, the duo had entered a collaboration agreement which granted Simnova exclusive rights to exploit Orna’s in vivo cell therapy products specifically in the Greater China area, including the promising ORN-101 project that targets CD19.
Vision for Patient Care
Dr. Ansbert Gadicke, Chairman of Orna and Managing Partner at MPM BioImpact, expressed enthusiasm over this enhanced collaboration, stating, “We are thrilled to deepen our partnership with Simnova to introduce an in vivo BCMA panCAR therapy specifically for patients suffering from multiple myeloma.” He emphasized that Orna’s unique panCAR approach aims to transcend the limitations associated with conventional ex vivo cell therapies. The pre-clinical and non-human primate data produced by Orna continues to reinforce their commitment to advancing these groundbreaking therapies toward clinical practice.
Dr. Zhuoxiao Cao, the CEO of Simnova, echoed these sentiments, affirming that their mutual dedication to developing immunotherapies and oncology treatments presents new avenues for addressing urgent medical needs through the strategic development of BCMA-targeted therapeutics.
About Orna Therapeutics
Orna Therapeutics is at the forefront of designing and delivering a new class of fully engineered circular RNA therapeutics, intended to harness the transformative potential of RNA medicine in combating a variety of diseases. The company’s circular RNA transcripts offer several advantages over traditional mRNA technologies, particularly in terms of simplified production processes and enhanced protein expression through advanced lipid nanoparticle (LNP) delivery systems. Their robust capabilities position Orna as a key player in the evolution of RNA therapeutics, with the potential to significantly enhance patient treatment paradigms.
About Simnova Biotech
Shanghai Simnova Biotech, dedicated to pioneering innovative cell therapy solutions for oncology and autoimmune diseases, boasts a rich research and development pipeline, highlighted by their proprietary universal off-the-shelf CAR-NK and BiTE CAR-T programs. With several products currently at various stages of clinical development, Simnova is poised to make substantial contributions to the realm of biotherapeutics.
For more information, visit Orna Therapeutics at www.ornatx.com and Simnova Biotech at www.simnovabio.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.